Welcome!
Home iX Biopharma
Company in the news
iX Biopharma completes first phase of its study for dementia-related agitation drug
The drug is being developed to treat dementia-related agitation, a condition where no drug treatment has been approved so far.
February 10, 2023
Broker's Calls
Broker's Digest: Spotify, NetLink NBN Trust, TDCX, iX Biopharma, StarHub
See what the analysts have to say this week.
October 06, 2022
Broker's Calls
PhillipCap slashes target price on iX Biopharma, but maintains ‘buy’ call
PhillipCap's Paul Chew has cut its target price by almost 30%, from 35.5 cents to 25 cents.
October 03, 2022
Medtech
iX Biopharma launches sublingual dexmedetomidine wafer to treat agitation in dementia and other indications
The global acute agitation and aggression treatment market size is projected to expand to US$7.09 billion by 2031.
August 29, 2022
Results
iX Biopharma reports loss for FY2022 despite eight-fold rise in revenue
The revenue surge was mainly driven by the upfront payment received from the group’s Wafermine out-licensing deal with Seelos.
August 23, 2022
Equity raising
iX Biopharma to raise $2.7 mil placing out new shares at premium to current market price
The placement price of 20 cents is a 15% premium to the company’s volume-weighted average price of 17.43 cents on July 12.
July 12, 2022
Results
iX Biopharma reverses from losses to net profit of $3.7 mil in 1HFY2022 from out-licensing of Wafermine
Eddy Lee, chairman and CEO of iX Biopharma, called the positive results a "significant inflection" for the business.
February 11, 2022
Corporate moves
iX Biopharma aims for stronger growth momentum with Seelos licensing deal
iX Biopharma announces an outlicensing agreement worth more than $300 million (excluding royalties) with Seelos Therapeutics
January 13, 2022
Broker's Calls
iX Biopharma 'warming up' with new outlicensing agreement with Seelos Therapeutics: PhillipCapital
PhillipCapital analyst Paul Chew maintains “buy” rating on iX Biopharma with an increased target price to 35.5 cents
December 01, 2021
Healthcare
iX Biopharma inks exclusive agreement with Seelos worth up US$239 mil
iX Biopharma will also receive double digit percentage royalties on future net sales of any licensed product.
November 24, 2021